CinCor Pharma to Report Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on March 22, 2022 BOSTON, March 15, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC), a clinical-stage biopharmaceutical company focused on developing its lead clinical candidate, CIN-107, for the...

CinCor Pharma to Present at the 32nd Annual Oppenheimer Healthcare Conference BOSTON, March 03, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC) a clinical-stage biopharmaceutical company focused on developing its lead clinical candidate, CIN-107, for the treatment...

CinCor Pharma Appoints June Lee to Its Board of Directors BOSTON, Jan. 13, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC) today announced the appointment of the independent member June Lee, M.D. to the company’s Board of Directors. Dr. Lee...

CinCor Pharma Announces Pricing of Initial Public Offering BOSTON, Jan. 06, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (“CinCor”) (Nasdaq: CINC), a clinical-stage biopharmaceutical company focused on developing its lead clinical candidate, CIN-107, for...

CinCor Pharma Launches Roadshow for Proposed Initial Public Offering of Common Stock BOSTON, Jan. 03, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (“CinCor”), a clinical-stage biopharmaceutical company focused on developing its lead clinical candidate, CIN-107, for the treatment of...